Phase 2 trial in 22 adults with chronic hepatitis D on NA therapy: the primary endpoint (HDV RNA fall plus normal ALT at week 48) was met by 4/17 (24%) on JNJ-73763989 vs 0/5 on placebo; ALT elevations led to stopping in 12/17 (71%).
RCTn = 22
Wedemeyer et al. siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares